JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 24, 2007; DOI: 10.1124/jpet.107.130062


0022-3565/08/3241-179-187$20.00
JPET 324:179-187, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.130062v1
324/1/179    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anderson, D. J.
Right arrow Articles by Gopalakrishnan, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderson, D. J.
Right arrow Articles by Gopalakrishnan, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NICOTINE
*NICOTINE TARTRATE

NEUROPHARMACOLOGY

[3H]A-585539 [(1S,4S)-2,2-Dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane], a Novel High-Affinity {alpha}7 Neuronal Nicotinic Receptor Agonist: Radioligand Binding Characterization to Rat and Human Brain

David J. Anderson, William Bunnelle, Bruce Surber, Jia Du, Carol Surowy, Eliane Tribollet, Anouk Marguerat, Daniel Bertrand, and Murali Gopalakrishnan

Neuroscience Research, Global Pharmaceutical Research & Development, Abbott Laboratories, Abbott Park, Illinois (D.J.A., W.B., B.S., J.D., C.S., M.G.); and Department of Neuroscience, Centre Médical Universitaire, Geneva, Switzerland (E.T., A.M., D.B.)

Receptor binding was characterized for [3H](1S,4S)-2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane ([3H]A-585539), a selective high-affinity {alpha}7 nicotinic acetylcholine receptor (nAChR) agonist with rapid kinetics, low nonspecific binding, and high specific activity. At 4°C, the association was monophasic and rapid (t1/2 = 8.0 min); dissociation was slower (t1/2 = 64.2 min). The Kd in rat brain at 4°C was 0.063 nM, whereas at 22 and 37°C, the Kd values were 0.188 and 0.95 nM, respectively. In contrast, the Bmax (34 fmol/mg protein) was unaffected by temperature. In human cortex, [3H]A-585539 bound with a Kd of 0.066 nM and a Bmax of 5.8 fmol/mg protein at 4°C, whereas under similar conditions, specific [3H]methyllycaconitine ([3H]MLA) binding was not measurable. A number of agonist and antagonist nAChR ligands displaced binding to rat brain membranes with rank order of affinity similar to that for [3H]MLA, and in general, a 5 to 10-fold higher affinity was observed for [3H]A-585539 binding. There was also a good correlation of Ki values between [3H]A-585539 binding to rat brain and human cortex. The use of a {alpha}7/5-hydroxytryptamine type-3 chimera revealed that the N-terminal domain of {alpha}7 nAChR was sufficient to faithfully reproduce the pharmacology of [3H]A-585539 binding. Autoradiographic studies comparing [3H]A-585539 and [125I]{alpha}-bungarotoxin revealed a similar pattern of labeling in the rat. In summary, [3H]A-585539 was shown to have excellent binding characteristics in rat and human brain and represents the first high-affinity {alpha}7 agonist radioligand with utility in the characterization of this important nAChR subtype that is targeted toward ameliorating cognitive deficits underlying neuropsychiatric and neurodegenerative disorders.


Address correspondence to: David J. Anderson, R-47W, AP9A, Abbott Laboratories, Abbott Park, IL 60064-6125. E-mail: david.j.anderson{at}abbott.com




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
J. Malysz, J. H. Gronlien, D. J. Anderson, M. Hakerud, K. Thorin-Hagene, H. Ween, C. Wetterstrand, C. A. Briggs, R. Faghih, W. H. Bunnelle, et al.
In Vitro Pharmacological Characterization of a Novel Allosteric Modulator of {alpha}7 Neuronal Acetylcholine Receptor, 4-(5-(4-Chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), Exhibiting Unique Pharmacological Profile
J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 257 - 267.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.